Histogen to Report Third Quarter 2021 Financial Results on November 10, 2021

10/27/21 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $HSTO alert in real time by email

SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that Histogen's financial results for the third quarter will be released after the close of market on Wednesday, November 10, 2021.

About Histogen Inc.

Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Histogen's innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen's proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications, including joint cartilage regeneration, spinal disk repair, tendon, ligament and other soft tissue repair. For more information, please visit www.histogen.com.

CONTACT:

Susan A. Knudson

Executive Vice President & CFO

Histogen Inc.

[email protected]

Get the next $HSTO alert in real time by email

Histogen to Report Third Quarter 2021 Financial Results on November 10, 2021

Chat with this insight

Recent Analyst Ratings for $HSTO

$HSTO Press Releases

Fastest customizable press release news feed in the world

Histogen Announces Second Adjournment of Special Meeting of Stockholders

Histogen Announces Adjournment of Special Meeting of Stockholders

Histogen Announces Board Approval of Complete Liquidation and Dissolution

$HSTO Market Insights

Live Market Insights

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

Why Cal-Maine Foods Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

$HSTO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. initiated coverage on Histogen with a new price target

Canaccord Genuity reiterated coverage on Histogen with a new price target

Canaccord Genuity initiated coverage on Histogen with a new price target

$HSTO Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Histogen Inc. (Amendment)

SEC Form SC 13G/A filed by Histogen Inc. (Amendment)

SEC Form SC 13G/A filed by Histogen Inc. (Amendment)

$HSTO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$HSTO Leadership Updates

Live Leadership Updates

$HSTO Financials

Live finance-specific insights

SEC Form 4 filed by Windham-Bannister Susan Richards

SEC Form 4 filed by Satz Brian

SEC Form 4 filed by Kisner Daniel L

Histogen Hires Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer

CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors

Orhub's Ryan Fernan Becomes Head Of Pur Biologics, Leading Regenerative Therapeutic Efforts

Histogen Reports Year-End 2022 Results and Provides Business Update

Histogen Reports Third Quarter 2022 Financial Results and Provides Business Update

Histogen Reports Second Quarter 2022 Financial Results and Provides Business Update

$HSTO SEC Filings

SEC Form 15-12G filed by Histogen Inc.

SEC Form DEFA14A filed by Histogen Inc.

SEC Form 425 filed by Histogen Inc.

Recent Analyst Ratings for
$HSTO

$HSTO
Press Releases

$HSTO
Market Insights

$HSTO
Analyst Ratings

$HSTO
Large Ownership Changes

$HSTO
Insider Trading

$HSTO
Leadership Updates

$HSTO
Financials

$HSTO
SEC Filings